| Field | Specification |
|---|---|
| Target | |
| Alternative names | B-cell antigen receptor complex-associated protein beta chain;B-cell-specific glycoprotein B29;Ig-beta;Immunoglobulin-associated B29 protein;CD79b;CD79B;B29, IGB; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human CD79b recombinant protein (Position: A29-E229). Human CD79b shares 70% amino acid (aa) sequence identity with mouse CD79b. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes B-cell antigen receptor complex-associated protein beta chain (gene CD79B) in human samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 26.0 kDa, and the supplier reports an observed band at about 30–40 kDa.
CD79b (Igβ) forms a heterodimer with CD79a that carries the signaling function of the B-cell antigen receptor. Its ITAM motif drives signaling after antigen engagement, and it is needed for B-cell development and is studied in B-cell lymphomas that depend on chronic receptor signaling.
| Target | B-cell antigen receptor complex-associated protein beta chain (gene CD79B; UniProt P40259, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 26.0 kDa |
| Observed MW | 30–40 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human Raji cells, human Daudi cells, human Ramos cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 10% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human spleen tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): human spleen tissue.
Samples with a confirmed signal (flow cytometry): Raji cells.
Immunogen
Recombinant human CD79b fragment (Ala29–Glu229), expressed in E. coli. Sequence identity with the mouse ortholog: 70%.
Reactivity Notes
The supplier lists reactivity with human. UniProt places B-cell antigen receptor complex-associated protein beta chain in the cell membrane. Tissue expression noted by UniProt (human): B-cells. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
